{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T17:52:04Z","timestamp":1778953924438,"version":"3.51.4"},"reference-count":40,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":214,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1124\/dmd.123.001434","type":"journal-article","created":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T16:40:12Z","timestamp":1706114412000},"page":"516-525","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["HCV Antiviral Drugs Have the Potential to Adversely Perturb the Fetal-Maternal Communication Axis through Inhibition of CYP3A7 DHEA-S Oxidation"],"prefix":"10.1016","volume":"52","author":[{"given":"Hannah M.","family":"Work","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4923-2668","authenticated-orcid":false,"given":"John C.","family":"Hackett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0794-2263","authenticated-orcid":false,"given":"Jed N.","family":"Lampe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.123.001434_bib1","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1111\/liv.14913","article-title":"Pregnancy outcome of anti-HCV direct-acting antivirals: real-life data from an Egyptian cohort","volume":"41","author":"AbdAllah","year":"2021","journal-title":"Liver Int"},{"key":"10.1124\/dmd.123.001434_bib2","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/cld.668","article-title":"Drug-drug interactions in hepatitis C virus treatment: do they really matter?","volume":"10","author":"Ahmed","year":"2017","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"10.1124\/dmd.123.001434_bib3","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1365-2893.2010.01413.x","article-title":"Hepatitis C virus infection during pregnancy and the newborn period\u2014are they opportunities for treatment?","volume":"18","author":"Arshad","year":"2011","journal-title":"J Viral Hepat"},{"key":"10.1124\/dmd.123.001434_bib4","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S2468-1253(21)00472-6","article-title":"Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study","volume":"7","author":"Blach","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1124\/dmd.123.001434_bib5","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s40262-014-0222-6","article-title":"Characterization of the transmembrane transport and absolute bioavailability of the HCV protease inhibitor danoprevir","volume":"54","author":"Brennan","year":"2015","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.123.001434_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/S2666-5247(20)30062-8","article-title":"Ledipasvir plus sofosbuvir in pregnant women with hepatitis C virus infection: a phase 1 pharmacokinetic study","volume":"1","author":"Chappell","year":"2020","journal-title":"Lancet Microbe"},{"key":"10.1124\/dmd.123.001434_bib7","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.3389\/fphar.2018.01027","article-title":"Physiology and pathophysiology of steroid biosynthesis, transport and metabolism in the human placenta","volume":"9","author":"Chatuphonprasert","year":"2018","journal-title":"Front Pharmacol"},{"key":"10.1124\/dmd.123.001434_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11904-022-00643-9","article-title":"Evidence for Implementation: HIV\/HCV coinfection and pregnancy","volume":"20","author":"Curtis","year":"2023","journal-title":"Curr HIV\/AIDS Rep"},{"key":"10.1124\/dmd.123.001434_bib9","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s12884-021-04158-w","article-title":"Prediction of miscarriage in first trimester by serum estradiol, progesterone and \u03b2-human chorionic gonadotropin within 9\u2009weeks of gestation","volume":"22","author":"Deng","year":"2022","journal-title":"BMC Pregnancy Childbirth"},{"key":"10.1124\/dmd.123.001434_bib10","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41575-020-00392-3","article-title":"Hepatitis C virus elimination: laying the foundation for achieving 2030 targets","volume":"18","author":"Dore","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1124\/dmd.123.001434_bib11","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S2468-1253(20)30359-9","article-title":"Global prevalence of hepatitis C virus in women of childbearing age in 2019: a modelling study","volume":"6","author":"Dugan","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1124\/dmd.123.001434_bib12","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1007\/s40262-015-0299-6","article-title":"Asunaprevir: a review of preclinical and clinical pharmacokinetics and drug\u2013drug interactions","volume":"54","author":"Eley","year":"2015","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.123.001434_bib13","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/apt.15476","article-title":"Review article: direct-acting antivirals for the treatment of HCV during pregnancy and lactation\u2014implications for maternal dosing, foetal exposure, and safety for mother and child","volume":"50","author":"Freriksen","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1124\/dmd.123.001434_bib14","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/s41598-023-27668-3","article-title":"Prevalence and factors associated with hepatitis C among pregnant women in China: a cross-sectional study","volume":"13","author":"He","year":"2023","journal-title":"Sci Rep"},{"key":"10.1124\/dmd.123.001434_bib15","doi-asserted-by":"crossref","first-page":"7098","DOI":"10.1128\/AAC.01044-16","article-title":"Pharmacokinetics of the new hepatitis C virus NS3 protease inhibitor narlaprevir following single-dose use with or without ritonavir in patients with liver cirrhosis","volume":"60","author":"Isakov","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/dmd.123.001434_bib16","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1021\/acs.chemrestox.1c00028","article-title":"Inhibition of CYP3A7 DHEA-S oxidation by lopinavir and ritonavir: an alternative mechanism for adrenal impairment in HIV antiretroviral-treated neonates","volume":"34","author":"Kandel","year":"2021","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.123.001434_bib17","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1159\/000356916","article-title":"Adrenal enzyme impairment in neonates and adolescents treated with ritonavir and protease inhibitors for HIV exposure or infection","volume":"81","author":"Kariyawasam","year":"2014","journal-title":"Horm Res Paediatr"},{"key":"10.1124\/dmd.123.001434_bib18","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1093\/cid\/ciz888","article-title":"Lopinavir-ritonavir impairs adrenal function in infants","volume":"71","author":"Kariyawasam","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1124\/dmd.123.001434_bib19","article-title":"Experiences and perspectives from women taking investigational therapy for hepatitis C virus during pregnancy","volume":"15","author":"Kislovskiy","year":"2021","journal-title":"Subst Abuse"},{"key":"10.1124\/dmd.123.001434_bib20","doi-asserted-by":"crossref","first-page":"13534","DOI":"10.1016\/S0021-9258(19)76460-6","article-title":"P-450 HFLa, a form of cytochrome P-450 purified from human fetal livers, is the 16 alpha-hydroxylase of dehydroepiandrosterone 3-sulfate","volume":"262","author":"Kitada","year":"1987","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.123.001434_bib21","doi-asserted-by":"crossref","first-page":"326","DOI":"10.3350\/cmh.2018.0063","article-title":"Ombitasvir\/paritaprevir\/ritonavir+dasabuvir and ribavirin associated drug-induced liver injury and syndrome of inappropriate secretion of anti-diuretic hormone: a case report","volume":"25","author":"Kumar","year":"2019","journal-title":"Clin Mol Hepatol"},{"key":"10.1124\/dmd.123.001434_bib22","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.3390\/v4123531","article-title":"Pathogenesis of hepatitis C during pregnancy and childhood","volume":"4","author":"Le Campion","year":"2012","journal-title":"Viruses"},{"key":"10.1124\/dmd.123.001434_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.abb.2019.108078","article-title":"Neonatal cytochrome P450 CYP3A7: a comprehensive review of its role in development, disease, and xenobiotic metabolism","volume":"673","author":"Li","year":"2019","journal-title":"Arch Biochem Biophys"},{"key":"10.1124\/dmd.123.001434_bib24","article-title":"Human cytochrome P450 3A7 binding four copies of its native substrate dehydroepiandrosterone 3-sulfate","volume":"299","author":"Liu","year":"2023","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.123.001434_bib25","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1111\/bcp.12873","article-title":"Pharmacokinetics and tolerability of paritaprevir, a direct acting antiviral agent for hepatitis C virus treatment, with and without ritonavir in healthy volunteers","volume":"81","author":"Menon","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.123.001434_bib26","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.2147\/DDDT.S254754","article-title":"Danoprevir for the treatment of hepatitis C virus infection: design, development, and place in therapy","volume":"14","author":"Miao","year":"2020","journal-title":"Drug Des Devel Ther"},{"key":"10.1124\/dmd.123.001434_bib27","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/hep.26141","article-title":"Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence","volume":"57","author":"Mohd Hanafiah","year":"2013","journal-title":"Hepatology"},{"key":"10.1124\/dmd.123.001434_bib28","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ejogrb.2018.03.034","article-title":"Mother-to-child transmission of hepatitis C virus","volume":"224","author":"Pott","year":"2018","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1124\/dmd.123.001434_bib29","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1124\/dmd.116.074518","article-title":"Mechanisms and predictions of drug\u2013drug interactions of the hepatitis C virus three direct-acting antiviral regimen: paritaprevir\/ritonavir, ombitasvir, and dasabuvir","volume":"45","author":"Shebley","year":"2017","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.123.001434_bib30","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1124\/dmd.115.067488","article-title":"Metabolism and disposition of the hepatitis C protease inhibitor paritaprevir in humans","volume":"44","author":"Shen","year":"2016","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.123.001434_bib31","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1177\/2050640616678151","article-title":"The majority of hepatitis C patients treated with direct acting antivirals are at risk for relevant drug\u2013drug interactions","volume":"5","author":"Smolders","year":"2017","journal-title":"United European Gastroenterol J"},{"key":"10.1124\/dmd.123.001434_bib32","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1007\/s40262-019-00774-0","article-title":"Viral hepatitis C therapy: pharmacokinetic and pharmacodynamic considerations: a 2019 update","volume":"58","author":"Smolders","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.123.001434_bib33","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/infdis\/jix495","article-title":"Hepatic pharmacokinetics and pharmacodynamics with ombitasvir\/paritaprevir\/ritonavir plus dasabuvir treatment and variable ribavirin dosage","volume":"217","author":"Talal","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1124\/dmd.123.001434_bib34","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/nrgastro.2016.176","article-title":"Global epidemiology and burden of HCV infection and HCV-related disease","volume":"14","author":"Thrift","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1124\/dmd.123.001434_bib35","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1124\/dmd.106.011304","article-title":"Helices F-G are important for the substrate specificities of CYP3A7","volume":"35","author":"Torimoto","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.123.001434_bib36","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-98219-x","article-title":"Characterization of fluorescent probe substrates to develop an efficient high-throughput assay for neonatal hepatic CYP3A7 inhibition screening","volume":"11","author":"Work","year":"2021","journal-title":"Sci Rep"},{"key":"10.1124\/dmd.123.001434_bib37","article-title":"The burden of hepatitis C virus in the world, China, India, and the United States from 1990 to 2019","volume":"11","author":"Yang","year":"2023","journal-title":"Front Public Health"},{"key":"10.1124\/dmd.123.001434_bib38","doi-asserted-by":"crossref","first-page":"643","DOI":"10.4254\/wjh.v6.i9.643","article-title":"Vertical transmission of hepatitis C virus: current knowledge and perspectives","volume":"6","author":"Yeung","year":"2014","journal-title":"World J Hepatol"},{"key":"10.1124\/dmd.123.001434_bib39","doi-asserted-by":"crossref","first-page":"62","DOI":"10.4274\/MMJ.galenos.2022.22747","article-title":"How to manage low estriol levels in pregnancies, one center experience","volume":"37","author":"Yilmaz Gulec","year":"2022","journal-title":"Medeni Med J"},{"key":"10.1124\/dmd.123.001434_bib40","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1002\/jmv.27877","article-title":"Sofosbuvir-based therapy for late pregnant women and infants with severe chronic hepatitis C: A case series study","volume":"94","author":"Zeng","year":"2022","journal-title":"J Med Virol"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624006883?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624006883?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.123.001434","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T18:01:27Z","timestamp":1740765687000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624006883"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S0090955624006883"],"URL":"https:\/\/doi.org\/10.1124\/dmd.123.001434","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HCV Antiviral Drugs Have the Potential to Adversely Perturb the Fetal-Maternal Communication Axis through Inhibition of CYP3A7 DHEA-S Oxidation","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.123.001434","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by The Author(s)","name":"copyright","label":"Copyright"}]}}